Thank you, Pasi. Welcome to all of you. And let's start.
Going into an overview of Q2, as we had communicated before, Q2 faced very high comparables. So we landed in revenue at €195.5 million, which was a -19.7%, pretty much in line with what we were expecting from the quarter. Therefore, I will say the main focus of the quarter was to defend profitability in a market that was more volatile and more challenging. And there I think that we did a good job maintaining €13.9 million of operating profit, which was 7.1% in line, actually, with our long-term target corridors that we communicated earlier in our capital market day earlier in the year.
It was quite pleasing to come to that level of profit in such market conditions. As I mentioned, turnover was declining, which was expected. However, during the quarter we started to see signs of recovery in one of the market segments we have, which is Medtech & Life Science. I will explain a bit more about it later. We realized the outcome of the efficiency program we had put in place and worked on already last quarter last year, and it came into full action during this quarter.
It allowed us to balance the revenue by lowering costs. We also continued the work we had on improving our working capital, reducing inventory, which had a positive effect on our cash position. At the same time, even if we were in a defensive mode regarding costs and delivering profitability, we continued to work on strategic initiatives we had launched earlier. Both Dream Factory implementation and the commercial plan we have with implementation of our three segments are now fully in place and working towards our customer and also acquiring new contracts.
So, a lot of activities, and looking at a few key events, were significant in the quarter. We won a project worth €40 million. And I will go a bit more in detail later. But we have now decided that we will, on a quarterly basis, give you the number of projects won when we get them in the company. So 40 million was a solid number and a few contracts came on board.
The one we have here on the screen is the contract we signed with Framery, where we are actually doing system integration and building those small offices that you can see in the picture. So, it's an exciting, very exciting business. We are very proud to become a supplier for those customers and to bring new solutions to life in the market for them, as well as drive development. Our management team is evolving, and we are pleased with the progress. We were happy to announce during the quarter that Anette Mullis will join us as Chief People Officer. At this stage, where our focus is on growing the company and building competencies, it's crucial. So, Anita is definitely the right profile with the experience we believe will help us move forward. We also continue to concentrate on quality delivery. On-time delivery was again above 98% for the quarter, which was very pleasing. We were very gratified to be recognized for our work. Our Dream Factory was praised by Danfoss Sensing Solutions for the outstanding performance. It was particularly gratifying to share this because it materializes what we have been discussing regarding the performance of our deliveries and how people appreciate the results of our programs. Furthermore, we are gaining momentum in manufacturing electronic components in Atlanta, with several new customers utilizing our facilities there. This progress is step by step and gaining momentum, recalling the key investments we made last year.
There were several events during that quarter that were quite pleasing to see, even considering the market conditions; for instance, our revenue development, as mentioned previously, reached approximately €95.5 million. From a supply perspective, we now have very few Price Volume Variance (PPV) issues affecting our revenue. Now, our revenue increasingly comes from product delivery and added value. This aspect has normalized over time. Regarding operating profit, as mentioned earlier, it was heartening to see that we reached €13.9 million in operating profit. This represents one of the top four quarterly profits in terms of profitability and value for Scanfil, which, given the market conditions, is quite pleasing. The 7.1% operating margin also fell within our targeted margin range. A big thanks to all our teams who have continuously worked on enhancing efficiency and maintaining control over the cost base, which is always reassuring to see no matter the business cycle.
At the same time, we continue to diversify our customer portfolio. Today, our largest customer makes up 12% of our business, and the top ten, excluding the largest, account for 42%. We have a very well-balanced portfolio, which is beneficial as it provides us with long-term stability and potential growth opportunities. Many of these customers, who do not fully own their manufacturing needs, are growing daily. This growth presents new opportunities as we move forward. Looking at the different segments now, on the revenue side, the industrial sector declined 19.6% during the quarter, which was, as previously stated, somewhat anticipated. We had very high comparables from the previous year. And we believe that last year was somewhat of a bubble quarter, with component shortages and supply chain panic. Thus, it declined by 19.6%. Looking at the first half of the year, we achieved revenue of about €35 million in that sector, which we believe is conducive to future growth. We have acquired a few sizable contracts, bringing in a decent segment with about 13 million. If you put them together, that will actually be materializing in 6 to 18 months, depending on which contract we are talking about. So, those were the developments we had in the quarter. Moving now to Energy & Cleantech. Energy & Cleantech declined 26.1% in the quarter. And they are more prevalent than anywhere else. I mean, we were really facing a bubble quarter last year, and therefore I think that we should view those numbers with a critical eye and feel like, okay, this is what it was. What is interesting to see, however, are two things: the dynamics. We continue to see new projects. During that quarter, we secured 22 million in new contracts for that segment. Since the beginning of the year, we have secured €38 million in new contracts. And I think it shows two things. It shows the long-term dynamics of these sectors that are clearly going to continue to grow and develop over the long term. And it also shows that we are seen as a very reliable partner. Supplier in that sector with the value we acquired in the quarter. So, it's a positive development. We can only say we gained customers in that segment. There is no loss of customers. They move to us more and more, transferring more products to us from existing customers, and new customers also come on board. So that was the outcome of those new rounds we had. And then, Medtech & Life Science was declining by 4.9% in the quarter. Uh, which was, I will say, getting very close to stabilization in numbers. And in reality, when you look at the dynamics of the quarter. I mean, we had a slight rebound towards the end of the quarter. The same goes for acquiring new projects, where month after month we are gaining momentum. We have acquired a bit more than €12 million of new projects since the beginning of the year. Uh, they are projects that will bring growth in the long term. And we have a lot of traction right now in discussions, both with existing customers who are reducing their supplier base and moving more projects to us, but also with new customers who recognize our capabilities. Here we have two factories that are in the forefront, Chuchu and Sierra, where we have quite a lot of interest for the Medtech & Life Science segment. I will hand over to Kai for the financials.